impact-subcutaneous-mastectomy-under-laparoscopy-with-situ-prosthetic

Impact of Subcutaneous Mastectomy under Laparoscopy with <em>In Situ</em> Prosthetic Reconstruction on Aesthetic Appearance in Breast Cancer Patients

Breast cancer remains one of the most widespread malignant tumors affecting women, with a range of treatment options available, among which surgical ...

comparative-study-dda-dia-acquisition-modes-on-uplc-q-orbitrap-mass

Comparative Study of DDA and DIA Acquisition Modes on UPLC-Q-Orbitrap Mass Spectrometry Using Huaihua Powder

This study systematically evaluates the comparative performance of two mass spectrometry acquisition modes, data-dependent acquisition (DDA) and ...

construction-human-breast-cancer-organoids-comet-assaybased

Construction of Human Breast Cancer Organoids and Comet Assay&#8211;Based Quantification of Doxorubicin-Induced DNA Damage

Breast cancer is the most common malignancy among women worldwide and exhibits substantial heterogeneity. Doxorubicin (DOX) is widely used in breast ...

Wuzhong People's Hospital

Shizuishan Maternal and Child Health Hospital

Wuzhong People's Hospital of Suzhou City

Breast cancer is a malignant tumor that is harmful to women's health around the world. Investigating the biological mechanism is, therefore, of pivotal importance to improve patients' prognoses. Compared to non-neoplastic tissues, enhanced glucose and lipid metabolism is one of the most common properties of malignant breast cancer. Adenosine triphosphate (ATP) citrate lyase is a key enzyme linking aerobic glycolysis and fatty acid synthesis and is of high biological and prognostic significance in breast cancer. In our clinical study, fresh clinical tissues were used to analyze ATP citrate lyase expression by western blotting, and paraffin archived samples from 62 breast cancer patients were used to analyze ATP citrate lyase expression by immunohistochemistry. In the cellular study, following small interfering RNA-mediated inhibition of ATP citrate lyase in MCF-7 cells, cell viability and apoptosis were measured using the Cell Counting Kit-8 and flow cytometry, respectively. Breast cancer tissues showed strong expression of ATP citrate lyase, whereas adjacent normal tissues showed weak expression. Silencing of endogenous ATP citrate lyase expression by small interfering RNA in MCF-7 cells suppressed cell viability and increased cell apoptosis. Collectively, our study revealed that expression of ATP citrate lyase was significantly increased in breast cancer tissue compared with normal tissue. In addition, we found that depletion of ATP citrate lyase suppressed tumor growth, which suggests that ATP citrate lyase-related inhibitors might be potential therapeutic approaches for breast cancer.

ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis.

Triple-negative breast cancer (TNBC) is a one of the subtypes of breast cancer which accounts for approximately 10-20% of all breast cancers. LncRNA XIST (XIST) is reported to be dysfunctional in numerous tumor types and is involved in the key pathways of cancer initiation, progression and metastasis. Thus, in the present study, we explored the detailed molecular mechanism of XIST in TNBC. XIST was down-regulated in TNBC tissues and cell lines. Overexpressed XIST inhibited cell proliferation, epithelial mesenchymal transition (EMT) and induced apoptosis  as well as suppressed TNBC tumor growth . MicroRNA (miR)- 454 was up-regulated in TNBC tissues and cell lines. Knockdown of miR-454 inhibited TNBC progression by suppressing cell proliferation, EMT and inducing cell apoptosis. Moreover, miR-454 was predicted and confirmed to be a target of XIST, and rescue assay indicated that overexpressed miR-454 could reverse XIST restoration mediated-anti-tumor effects on TNBC cells. In conclusion, XIST interacts with miR-454 to inhibit cells proliferation, EMT and induce apoptosis in TNBC, indicating a promising treatment strategy for TNBC patients.

LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer.

Tamoxifen is widely used as a highly effective drug for treating estrogen‑receptor (ER) alpha‑positive breast cancer. However, tamoxifen resistance developed during cancer treatment remains a significant challenge. Tongue cancer resistance‑related protein1 (TCRP1), which is recognized as a novel drug target, is related to chemo‑resistance in human cancers, moreover, it is often overexpressed in various cancer cells, such as in lung cancer, breast cancer, and tongue cancer. However, the effects of TCRP1 on tamoxifen‑resistant breast cancer cells and tissues are far from clear. The present study revealed that TCRP1 induced tamoxifen resistance in breast cancer cells. Western blotting, quantitative real‑time polymerase chain reaction (RT‑PCR) and immunohistochemical staining were performed to detect the expression level of TCRP1 in vivo and in vitro between primary breast cancer tissues and tamoxifen‑resistant breast cancer tissues. The data revealed that the expression of TCRP1 was upregulated in the tamoxifen‑resistant breast cancer tissues and human breast cancer cell line, MCF‑7. Further study revealed that knocking down TCRP1 inhibited the growth of MCF‑7 cells with tamoxifen‑resistance (MCF7‑R cells) and induced cell apoptosis. Moreover, TCRP1 promoted serum‑ and glucocorticoid‑inducible kinase 1 (SGK1) activation via phosphorylation of phosphoinositide‑dependent kinase 1 (PDK1) in MCF7‑R cells. In addition, it was also observed that knocking down TCRP1 inhibited tumorigenesis of MCF‑7 cells in nude mice. In conclusion, these data indicated that TCRP1 could induce tamoxifen resistance by regulating the PDK1/SGK1 signaling pathway. Thus, TCRP1 could be explored as a promising candidate for treating tamoxifen‑resistant breast cancer in the future.

TCRP1 induces tamoxifen resistance by promoting the activation of SGK1 in MCF‑7 cells.

Regulation of inducers and transcription factor families influence epithelial-mesenchymal transition (EMT), a contributing factor to breast cancer invasion and progression.

Epithelial-Mesenchymal Transition-Based Gene Signature and Distinct Molecular Subtypes for Predicting Clinical Outcomes in Breast Cancer.

Insular thyroid carcinoma (ITC) is an uncommon poorly differentiated thyroid malignancy. Due to its rarity, its demographic and clinicopathological features and survival remains unclear. The present study aimed to describe the features and survival of ITC, determine its prognostic factors, and establish a prognostic nomogram.

Clinical characteristics and prognostic nomogram for patients with insular thyroid carcinoma: a population-based analysis.

The risk and prognosis of young breast cancer (YBC) with liver metastases (YBCLM) remain unclear. Thus, this study aimed to determine the risk and prognostic factors in these patients and construct predictive nomogram models.

Risk factors and survival prediction of young breast cancer patients with liver metastases: a population-based study.

The purpose of this study was to describe the clinicopathological characteristics and prognosis of primary small cell carcinoma of the breast (PSCCB) and compare PSCCB with breast invasive ductal carcinoma (IDC).

Clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.

Breast cancer (BC) is a lethal disorder that threatens the life safety of the majority of females globally, with rising morbidity and mortality year by year. Doxorubicin is a cytotoxic anthracycline antibiotic that is widely used as one of the first-line chemotherapy agents for patients with BC. However, the efficacy of doxorubicin in the clinic is largely limited by its serious side effects and acquired drug resistance. Allicin (diallyl thiosulfinate), as the major component and key active compound present in freshly crushed garlic, has shown potential effects in suppressing chemotherapy resistance in various cancers. Our research aimed to explore the relationship between allicin and doxorubicin resistance in BC. To generate doxorubicin-resistant BC cell lines (MCF-7/DOX and MDA-MB-231/DOX), doxorubicin-sensitive parental cell lines MCF-7 and MDA-MB-231 were continuously exposed to stepwise increased concentrations of doxorubicin over a period of 6 months. CCK-8, colony formation, flow cytometry, RT-qPCR, and western blotting assays were performed to investigate the effects of allicin and/or doxorubicin treatment on the viability, proliferation and apoptosis and the expression of Nrf2, HO-1, phosphate AKT and AKT in doxorubicin-resistant BC cells. Our results showed that combined treatment of allicin with doxorubicin exhibited better effects on inhibiting the proliferation and enhancing the apoptosis of doxorubicin-resistant BC cells than treatment with allicin or doxorubicin alone. Mechanistically, allicin suppressed the levels of Nrf2, HO-1, and phosphate AKT in doxorubicin-resistant BC cells. Collectively, allicin improves the doxorubicin sensitivity of BC cells by inactivating the Nrf2/HO-1 signaling pathway.

Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway.

This study systematically explored the dynamic evolution of bioactive components, flavor metabolites, and microbial communities in citri reticulatae pericarpium (CRP) throughout its processing from fresh materials through drying to controlled aging. Using UPLC, GC-MS, and high-throughput sequencing, we found that during the fresh-to-dry phase (0-7 days), water activity decreased significantly ( < 0.05), while total flavonoids, hesperidin, and volatile oil yield increased by 3.3 %-10.8 %. Drying at 30 °C enhanced microbial diversity ( < 0.05). In the dry-to-aged phase (7-360 days), total flavonoids accumulated, while volatile oil decreased by 50.7 %.  emerged as a dominant species from 270 to 360 days. Correlation analysis showed positive links between  and flavonoid levels ( < 0.05). This research provides a framework for monitoring CRP processing and highlights the impact of drying methods on quality through microbial diversity.

Dynamic profiling of bioactive compounds, flavor metabolites, and quality-related microorganisms during the freshening-drying-aging process of citri reticulatae pericarpium: Implications for quality formation mechanisms.

ArticleTotal : 3	Year
Publication title	2025
Publication title Cited by 1	2025
Publication title	2026

Article	Year
ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine\| PubMed ID: 28443474	2017
LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer. Journal of biosciences\| PubMed ID: 32098924	2020
TCRP1 induces tamoxifen resistance by promoting the activation of SGK1 in MCF‑7 cells. Oncology reports\| PubMed ID: 32323833	2020
Epithelial-Mesenchymal Transition-Based Gene Signature and Distinct Molecular Subtypes for Predicting Clinical Outcomes in Breast Cancer. International journal of general medicine\| PubMed ID: 35386860	2022
Clinical characteristics and prognostic nomogram for patients with insular thyroid carcinoma: a population-based analysis. Endocrine\| PubMed ID: 36207552	2023
Risk factors and survival prediction of young breast cancer patients with liver metastases: a population-based study. Frontiers in endocrinology\| PubMed ID: 37424855	2023
Clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study. BMJ open\| PubMed ID: 38097248	2023
Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway. Cell biochemistry and biophysics\| PubMed ID: 38411783	2024
Dynamic profiling of bioactive compounds, flavor metabolites, and quality-related microorganisms during the freshening-drying-aging process of citri reticulatae pericarpium: Implications for... Food chemistry: X\| PubMed ID: 40831970	2025

Lei Yin

Biography

JoVE Journal Publications

Other Publications